List of Excipients in Branded Drug FLUOCINOLONE ACETONIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Seton Pharmaceuticals	FLUOCINOLONE ACETONIDE	fluocinolone acetonide	13925-506	ISOPROPYL ALCOHOL
Seton Pharmaceuticals	FLUOCINOLONE ACETONIDE	fluocinolone acetonide	13925-506	ISOPROPYL MYRISTATE
Seton Pharmaceuticals	FLUOCINOLONE ACETONIDE	fluocinolone acetonide	13925-506	LIGHT MINERAL OIL
Seton Pharmaceuticals	FLUOCINOLONE ACETONIDE	fluocinolone acetonide	13925-506	OLETH-2

Generic Drugs Containing FLUOCINOLONE ACETONIDE

Company	Ingredient	NDC	Excipient
E Fougera & Co a division of Fougera Pharmaceuticals Inc	fluocinolone acetonide	0168-0058	CITRIC ACID MONOHYDRATE
E Fougera & Co a division of Fougera Pharmaceuticals Inc	fluocinolone acetonide	0168-0058	METHYLPARABEN
E Fougera & Co a division of Fougera Pharmaceuticals Inc	fluocinolone acetonide	0168-0058	POLYSORBATE 60
E Fougera & Co a division of Fougera Pharmaceuticals Inc	fluocinolone acetonide	0168-0058	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in FLUOCINOLONE ACETONIDE?

# Of NDCs	Excipient
6	ANHYDROUS CITRIC ACID
1	ARACHIS HYPOGAEA
1	BUTYLATED HYDROXYTOLUENE
2	CETYL ALCOHOL

Fluocinolone Acetonide Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Fluocinolone acetonide is a high-potency corticosteroid with commercial opportunities across topical creams, ointments, solutions, scalp oils, otic products, and sustained-release ophthalmic implants. The strongest excipient opportunities are in low-dose delivery systems that improve skin penetration, reduce irritation, control release, or extend product life after legacy topical products lose exclusivity.

Topical products compete mainly on vehicle performance, tolerability, cosmetic acceptability, packaging, and regulatory substitutability. Ophthalmic implants compete on polymer engineering, dose uniformity, release kinetics, surgical delivery, and device-related intellectual property. Fluocinolone acetonide itself is an established active pharmaceutical ingredient, so differentiation depends heavily on formulation and delivery technology.

What is fluocinolone acetonide used for?

Fluocinolone acetonide is a synthetic glucocorticoid used to reduce inflammation and pruritus in dermatologic and ophthalmic diseases. Its commercial applications include:

Product category	Typical strength or dose	Primary use	Representative product
Topical cream, ointment, gel, or solution	0.01% to 0.025%	Inflammatory dermatoses	Synalar and generics
Scalp oil	0.01%	Atopic dermatitis and scalp dermatoses	Derma-Smoothe/FS
Otic solution	0.01%	Steroid-responsive ear inflammation	Fluocinolone acetonide otic products
Intravitreal implant	0.18 mg	Chronic noninfectious posterior uveitis	Yutiq
Intravitreal implant	0.19 mg	Diabetic macular edema	Iluvien
Intravitreal implant	0.59 mg	Chronic noninfectious posterior uveitis	Retisert

The compound is potent at low concentrations, which allows manufacturers to use small active loads. That creates formulation flexibility but increases the importance of content uniformity, adsorption control, and analytical sensitivity.

What excipients are used in fluocinolone acetonide topical products?

Topical excipients determine drug release from the vehicle, partitioning into the stratum corneum, skin hydration, wash-off resistance, sensory profile, and preservative performance.

Cream and lotion vehicles

Fluocinolone acetonide creams commonly use an oil-in-water emulsion containing combinations of:

• Purified water
• Mineral oil
• Petrolatum or white petrolatum
• Stearyl alcohol
• Cetyl alcohol
• Glyceryl stearate
• Polysorbate or other nonionic emulsifiers
• Propylene glycol
• Carbomer or cellulose-based rheology modifiers
• Sodium hydroxide or other pH adjusters
• Preservatives such as parabens or phenoxyethanol, depending on the product

The main commercial advantage of a cream is broad patient acceptance. The principal technical challenge is maintaining a stable emulsion while keeping fluocinolone acetonide adequately solubilized or uniformly dispersed at very low concentration.

Propylene glycol can act as a humectant, cosolvent, and penetration enhancer. It can improve delivery but may cause burning or irritation, particularly on compromised skin. A manufacturer seeking pediatric, facial, or intertriginous use may pursue lower-irritancy cosolvent systems.

Ointment vehicles

Ointments typically rely on:

• White petrolatum
• Mineral oil
• Paraffin or microcrystalline wax
• Lanolin derivatives in some formulations
• Polyethylene or other structuring agents

Ointments provide occlusion and can increase hydration of the stratum corneum. They are useful for thick, dry, or lichenified lesions. Their commercial weakness is greasiness, poor cosmetic acceptance, and lower suitability for hair-bearing areas.

A differentiated ointment can use a lower-tack hydrocarbon system, silicone-compatible emollients, or a semi-solid structure designed to improve spreadability while preserving occlusion. These changes may support a formulation patent or an abbreviated new drug application if the product meets the relevant sameness and performance requirements.

Scalp oils

Derma-Smoothe/FS uses a low-concentration fluocinolone acetonide formulation in an oil vehicle. The product label identifies refined peanut oil as an inactive ingredient, making allergen control and labeling central commercial considerations (DailyMed, 2024a).

Scalp oil excipient strategies include:

• Mineral oil or alternative emollient oils
• Isopropyl myristate
• Medium-chain triglycerides
• Silicone fluids
• Antioxidants
• Low-viscosity spreading agents

An opportunity exists for peanut-oil-free products using highly purified mineral oil, medium-chain triglycerides, or synthetic ester systems. Such a product could target patients, caregivers, and prescribers seeking to avoid peanut-derived excipients. The commercial value depends on whether the product can preserve the wetting, spreading, rinseability, and drug-delivery profile of the reference formulation.

Solutions and sprays

Solution products may use:

• Water
• Alcohols
• Propylene glycol
• Polyethylene glycol
• Solubilizers
• pH modifiers
• Preservatives

Solutions can offer rapid application and low residue. Alcohol content can improve drying but increases stinging on inflamed or fissured skin. A low-alcohol or alcohol-free formulation may have an opportunity in sensitive-skin and pediatric segments, subject to acceptable drug release and microbial control.

What excipients are used in fluocinolone acetonide ophthalmic implants?

The ophthalmic implant market uses excipients as structural materials rather than conventional liquid or semi-solid formulation components.

Yutiq

Yutiq is an intravitreal implant containing 0.18 mg of fluocinolone acetonide for chronic noninfectious posterior uveitis. Its extended-release profile is based on a nonbiodegradable polymeric drug-delivery system, with release over approximately 36 months according to the prescribing information (DailyMed, 2024b).

The commercial formulation variables include:

• Polymer identity
• Polymer permeability
• Drug-polymer loading
• Implant dimensions
• Surface area
• Coating or membrane structure
• Release-rate controlling excipients
• Sterilization compatibility

The key development risk is dose dumping or release-rate drift after sterilization. A polymer system must maintain predictable delivery despite changes in drug particle size, residual solvent, implant geometry, and storage conditions.

Iluvien

Iluvien is a nonbiodegradable intravitreal implant containing 0.19 mg of fluocinolone acetonide. It is designed to release the corticosteroid over an extended period for diabetic macular edema in patients previously treated with corticosteroids without clinically significant intraocular pressure elevation (DailyMed, 2024c).

Iluvien’s commercial differentiation is based on sustained delivery and a specialized applicator. The formulation opportunity is therefore closely linked to device engineering. A competing product would need to establish comparable implant integrity, delivery accuracy, release kinetics, and clinical performance.

Retisert

Retisert contains 0.59 mg of fluocinolone acetonide and is surgically implanted in the vitreous cavity for chronic noninfectious posterior uveitis. The product uses a drug-core and polymeric release-control architecture rather than a conventional injectable suspension (DailyMed, 2024d).

Retisert demonstrates the value of a higher drug load and longer-duration implant, but its surgical implantation requirement creates a barrier to broad adoption. A newer implant with a smaller size, simplified insertion, or lower intraocular pressure risk could compete through device and excipient design rather than through the active ingredient.

What formulation patents protect fluocinolone acetonide products?

Formulation protection generally falls into five categories:

1. Vehicle composition patents. These cover specific oil, cream, emulsion, solvent, surfactant, or polymer combinations.
2. Particle-size and dispersion patents. These address micronized drug, suspension stability, and uniformity.
3. Release-control patents. These cover polymer composition, drug loading, implant geometry, membrane thickness, and release rate.
4. Method-of-use patents. These protect particular dosing schedules, disease populations, or treatment sequences.
5. Device patents. These cover implant applicators, insertion methods, and delivery configurations.

For topical generic products, the relevant commercial barrier is often less a single patent than the combination of formulation sameness, product-specific labeling, manufacturing controls, and substitution requirements. A generic can face approval delays if the reference product has a complex dosage form or if inactive ingredients affect local tolerability.

For ophthalmic implants, the patent estate is more technically concentrated. Polymer architecture and applicator design may create stronger barriers than the active pharmaceutical ingredient. The Orange Book lists patents and exclusivity associated with approved products, but patent coverage must be assessed product by product and jurisdiction by jurisdiction (FDA, 2024a).

When does fluocinolone acetonide lose exclusivity?

Fluocinolone acetonide as a chemical entity is long established and does not retain meaningful compound-patent exclusivity in the United States. Exclusivity risk is instead product-specific.

Product	Regulatory pathway	Main exclusivity issue
Legacy topical creams and ointments	NDA and ANDA products	Formulation sameness, labeling, and remaining listed patents
Derma-Smoothe/FS	NDA product	Vehicle composition and peanut-oil excipient profile
Yutiq	NDA product	Implant design, release kinetics, and device patents
Iluvien	NDA product	Implant and applicator patents, method-of-use coverage
Retisert	NDA product	Legacy implant and delivery technology

Small-molecule topical products generally face generic entry once relevant patents and regulatory exclusivities expire. Ophthalmic implants can retain practical market protection after basic patents expire because generic applicants must reproduce a complex drug-device product and demonstrate equivalent performance.

What is the Orange Book status of fluocinolone acetonide products?

Fluocinolone acetonide products can appear in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, when they are approved drug products subject to applicable listing requirements.

The Orange Book is most commercially relevant for:

• Listed patents on NDA products
• Paragraph IV certifications by ANDA applicants
• Therapeutic-equivalence ratings for generic topical products
• Reference listed drug identification
• Product-specific exclusivity

Topical creams, ointments, solutions, and oils can have multiple approved strengths and dosage forms. An Orange Book rating does not guarantee commercial interchangeability across every formulation or package configuration. A product may be pharmaceutically equivalent yet remain subject to practical substitution limits depending on the dosage form, prescriber behavior, state law, and payer policies.

Which companies are challenging fluocinolone acetonide products?

Generic manufacturers have historically supplied fluocinolone acetonide creams, ointments, solutions, and other topical forms. The competitive field can include:

• Large generic manufacturers
• Specialty dermatology companies
• Contract manufacturers with topical semisolid capabilities
• Ophthalmic drug-delivery companies
• Drug-device companies developing sustained-release implants

Paragraph IV activity is most commercially important for newer ophthalmic implants and differentiated topical products. A successful Paragraph IV challenge can accelerate entry but also exposes the challenger to patent litigation, a potential 30-month stay, and launch-at-risk damages. The timing depends on Orange Book listings, certification dates, litigation filings, and settlement terms under the Hatch-Waxman framework (FDA, 2024b).

What commercial opportunities exist for fluocinolone acetonide excipients?

Peanut-oil-free scalp formulations

A peanut-oil-free scalp oil is one of the clearest formulation opportunities. The product could retain the oil-based delivery model while replacing refined peanut oil with a nonallergenic excipient system.

The development target should include:

• Equivalent or improved drug deposition
• Comparable rinseability
• Lower odor and residue
• Stable low-dose content uniformity
• Preservative-free or low-preservative positioning where feasible
• Clear allergen labeling

A change in excipients may require a full product-specific regulatory strategy rather than a straightforward generic approach, particularly if the reference product’s formulation is complex.

Low-irritancy facial and pediatric products

A lower-stinging formulation could target areas where alcohol, propylene glycol, or high-solvent systems limit use. Candidate strategies include:

• Reduced propylene glycol concentration
• Alternative glycols
• Nonionic solubilizers
• Lamellar emulsions
• Barrier-supportive emollients
• Lower alcohol content

The commercial opportunity is strongest where patients discontinue treatment because of burning, greasiness, or poor cosmetic acceptance.

Foam, spray, and hydrogel dosage forms

Foams and sprays can improve application to the scalp and large body areas. Hydrogels can reduce residue and provide a cooling sensory profile. These dosage forms may support lifecycle management, but they introduce challenges in:

• Valve and propellant compatibility
• Drug crystallization
• Container closure integrity
• Dose uniformity per actuation
• Flammability
• Scale-up of low-concentration products

Long-acting ophthalmic implants

The largest technical opportunity is a smaller, less invasive implant with controlled release and reduced steroid exposure. Potential differentiators include:

• Biodegradable polymers
• Injectable in situ-forming systems
• Lower implant volume
• Longer duration
• More predictable zero-order release
• Lower cataract and intraocular-pressure burden
• Simplified office-based insertion

Biodegradable implants could reduce the need for surgical removal, but polymer degradation can create variability in acidity, particle formation, and release rate. Those risks require extensive stability, imaging, and ocular safety work.

Combination and co-delivery systems

Fluocinolone acetonide could be paired with anti-infective or barrier-supportive therapies in carefully defined indications. Combination products face additional regulatory and clinical requirements, but they may reduce treatment steps and improve adherence.

The main limitations are antimicrobial resistance concerns, steroid-related infection risk, and the need to establish a clinically justified combination rather than relying on formulation novelty alone.

How strong is the patent estate for fluocinolone acetonide?

The estate is weak at the active-ingredient level and stronger at the delivery-system level.

Technology layer	Relative protection	Commercial assessment
Fluocinolone acetonide molecule	Low	Long-established corticosteroid
Conventional cream or ointment	Low to moderate	Generic competition is extensive
Specialized oil formulation	Moderate	Excipient substitution and performance can differentiate
Ophthalmic implant polymer	Moderate to strong	Manufacturing and release testing create barriers
Implant applicator	Moderate to strong	Device patents and know-how can delay competition
Method of use	Variable	Strength depends on claim scope and validity
Manufacturing process	Moderate	Process know-how may be difficult to design around

A strong commercial position requires more than patent claims. Developers need proprietary analytical methods, implant manufacturing know-how, scale-up experience, validated sterilization, and reliable supply of specialty excipients.

What manufacturing and IP barriers affect fluocinolone acetonide?

Topical manufacturing barriers include low-dose blending, uniform dispersion, emulsion control, microbial limits, viscosity control, and filling accuracy. Small changes in particle size or mixing energy can affect drug release and content uniformity.

Ophthalmic implant manufacturing is more difficult. Critical parameters include:

• Drug-polymer homogeneity
• Implant dimensions
• Polymer molecular-weight distribution
• Residual solvents
• Sterility assurance
• Release testing over multiple years
• Applicator compatibility
• Container closure integrity

Specialty polymer sourcing can become a supply-chain risk. A developer that relies on a single qualified polymer vendor may face comparability work after a supplier change. The best commercial strategy is to qualify multiple sources early or develop a polymer specification broad enough to support controlled secondary sourcing.

How does fluocinolone acetonide compare with competing corticosteroids?

Active ingredient	Relative potency	Common formulation opportunity	Competitive issue
Fluocinolone acetonide	High	Low-dose topical and implant delivery	Established generic competition
Hydrocortisone	Low	Broad OTC and prescription products	Lower potency, high competition
Desonide	Low to moderate	Pediatric and facial formulations	Tolerability positioning
Triamcinolone acetonide	Moderate	Creams, ointments, injections	Broad generic availability
Mometasone furoate	High	Once-daily topical products	Strong branded and generic presence
Clobetasol propionate	Very high	Short-course dermatology products	Potency and safety restrictions

Fluocinolone acetonide is attractive when a developer wants high potency at a low drug load or sustained local exposure. It is less attractive when the commercial strategy depends only on the active ingredient, because the molecule is widely available and conventional topical products are heavily commoditized.

What generic launch risks exist?

Generic entry scenarios differ by dosage form.

Conventional topicals

The likely entry model is a conventional ANDA with pharmaceutical equivalence and comparative performance data. Price erosion can be rapid when multiple suppliers enter. Manufacturers with efficient semisolid production and strong pharmacy distribution are best positioned.

Complex topical products

Oils, foams, sprays, and emulsions may require more extensive characterization. Differences in excipients can affect local tolerability and drug release. The reference product’s inactive ingredients may also create a design constraint.

Ophthalmic implants

A generic or follow-on implant faces higher development costs, longer studies, and more complex equivalence questions. The competitor may need to establish comparable release kinetics, implant placement, dose delivery, and clinical safety. These requirements create a smaller competitive field and potentially slower price erosion.

What is the revenue exposure for fluocinolone acetonide products?

Revenue exposure is concentrated in differentiated ophthalmic implants and branded or specialty topical vehicles rather than commodity creams.

Revenue segment	Exposure to generic erosion	Strategic implication
Generic 0.01% and 0.025% topicals	High	Low-margin, volume-driven business
Branded scalp oil	Moderate	Vehicle and allergen profile support differentiation
Specialty foam or spray	Moderate	Device and formulation complexity can delay substitution
Ophthalmic implants	Lower initially	High development barrier and specialist prescribing
Improved biodegradable implant	Potentially low	New clinical value may support premium pricing

A branded owner with ophthalmic implant revenue has greater exposure to patent expiry and follow-on competition than a generic manufacturer. A generic manufacturer’s opportunity is the opposite: predictable volume in topical forms, with higher margins available in complex dosage forms.

What FDA regulatory strategy applies to new fluocinolone acetonide products?

The appropriate pathway depends on the formulation.

• Conventional topical cream or ointment: ANDA may be appropriate if the product can meet pharmaceutical-equivalence and bioequivalence expectations.
• Complex topical oil, foam, or spray: An ANDA remains possible, but development requires detailed comparative characterization and product-specific studies.
• New ophthalmic implant: An NDA or 505(b)(2) pathway may be appropriate, depending on the extent of reliance on the reference product and the degree of formulation or device change.
• Combination product: FDA may regulate the product as a drug, device, or combination product depending on the primary mode of action.

For ophthalmic implants, the regulatory package must address both drug quality and delivery-system performance. Release testing cannot rely solely on short-term assays because the intended product duration may span years.

What licensing deals are commercially relevant?

Licensing value is highest for companies that combine:

• A proprietary polymer or biodegradable implant platform
• A validated ophthalmic applicator
• A manufacturing site capable of sterile implant production
• Clinical data in uveitis or diabetic macular edema
• Freedom to operate around existing implant patents

Topical fluocinolone acetonide licensing is more likely to involve regional rights, contract development, or private-label supply than large platform transactions. Ophthalmic delivery technology can support broader licensing because the platform may apply to other corticosteroids or small-molecule drugs.

A practical transaction structure would typically separate rights by geography, indication, dosage form, and manufacturing responsibility. Royalty economics should reflect whether the licensor contributes only formulation know-how or also owns clinical data, regulatory approvals, patents, and commercial supply capacity.

What patent litigation and settlement issues affect the market?

Patent disputes are most likely around:

• Orange Book-listed implant patents
• Applicator and device claims
• Release-rate specifications
• Method-of-use claims
• Formulation claims covering polymer composition
• Paragraph IV certifications by generic or follow-on applicants

Settlements may include delayed generic entry, authorized generic rights, licensing, supply arrangements, or geographic restrictions. The commercial impact depends on the agreed entry date and whether the settlement permits an authorized generic before the challenger’s launch.

Topical products face more limited litigation value because the active ingredient and many conventional vehicles are old. Complex topical products and implants offer greater scope for enforceable claims, but their patents must be drafted around measurable formulation or performance characteristics rather than broad claims to fluocinolone acetonide use.

Key Takeaways

• Fluocinolone acetonide has limited molecule-level exclusivity but meaningful formulation and delivery-system opportunities.
• Conventional creams and ointments are mature, highly competitive generic products.
• Peanut-oil-free scalp oil is a clear excipient-led lifecycle opportunity.
• Low-irritancy, alcohol-reduced, foam, spray, and hydrogel products can target cosmetic and adherence limitations.
• Ophthalmic implants have the strongest commercial and IP potential because polymer architecture and applicator design create technical barriers.
• Generic entry risk is high for conventional topicals and lower for complex implants.
• Manufacturing know-how, sterilization, release testing, and polymer sourcing are central to competitive advantage.
• Licensing value is greatest for long-acting ophthalmic delivery platforms with validated clinical and manufacturing packages.

FAQs About Fluocinolone Acetonide Excipients and Commercial Strategy

Which fluocinolone acetonide excipient creates the clearest product differentiation?

Replacing refined peanut oil in scalp oil formulations with a nonallergenic oil system offers the clearest differentiated opportunity, provided drug delivery, rinseability, stability, and sensory performance remain comparable.

Can fluocinolone acetonide be formulated without propylene glycol?

Yes. Alternative glycols, polyethylene glycols, nonionic solubilizers, emulsions, and oil-based vehicles can be evaluated. The replacement must maintain solubility, uniformity, release, and skin tolerability.

Is fluocinolone acetonide suitable for a biodegradable ophthalmic implant?

Yes, technically. The primary risks are polymer degradation, variable release, ocular tolerability, particle formation, and long-term sterility assurance.

What is the strongest commercial dosage form for a new entrant?

A sustained-release ophthalmic implant has the highest barrier to entry and potential pricing power. For a lower-risk development program, a differentiated topical oil, foam, or spray is more practical.

Can a generic manufacturer copy the excipients in a fluocinolone acetonide product?

A generic manufacturer may use the same or different inactive ingredients, subject to FDA requirements and product-specific equivalence standards. Complex formulations may require more extensive comparative characterization than conventional creams or ointments.

References

1. DailyMed. (2024a). Derma-Smoothe/FS (fluocinolone acetonide) topical oil prescribing information. U.S. National Library of Medicine.

2. DailyMed. (2024b). Yutiq (fluocinolone acetonide intravitreal implant) prescribing information. U.S. National Library of Medicine.

3. DailyMed. (2024c). Iluvien (fluocinolone acetonide intravitreal implant) prescribing information. U.S. National Library of Medicine.

4. DailyMed. (2024d). Retisert (fluocinolone acetonide intravitreal implant) prescribing information. U.S. National Library of Medicine.

5. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2024b). Paragraph IV drug product approvals and patent certification resources. U.S. Department of Health and Human Services.